Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 661 - 670 of 1165

Daurismo (Glasdegib)

Status:

Negotiations were not pursued

Manufacturer:

Pfizer Canada ULC

Indication:

Acute Myeloid Leukemia (AML)

Last updated February 23, 2021

Nubeqa (Darolutamide)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Non-metastatic Castration-resistant prostate cancer

Last updated February 18, 2021

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Head and Neck Squamous Cell Carcinoma (HNSCC)

Last updated February 10, 2021

Vyndaqel (tafamidis)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Transthyretin-mediated amyloidosis

Last updated February 4, 2021

Aermony Respiclick (fluticasone propionate)

Status:

Concluded with an LOI

Manufacturer:

Teva Canada Ltd.

Indication:

Asthma

Last updated February 2, 2021

Monoferric (iron (iii) isomaltoside 1000)

Status:

Concluded with an LOI

Manufacturer:

Pharmacosmos A/S

Indication:

Iron Deficiency Anemia

Last updated February 2, 2021

Spravato (esketamine hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Janssen Inc.

Indication:

Major Depressive Disorder

Last updated January 27, 2021

Idacio (adalimumab)

Status:

Concluded with an LOI

Manufacturer:

Fresenius Kabi Canada Ltd.

Indication:

Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis

Last updated January 26, 2021

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

Bionime USA Corporation

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated January 22, 2021

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

ForaCare Technology Canada, Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated January 22, 2021

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 65
  • Page 66
  • Current page 67
  • Page 68
  • Page 69
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use